Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Jeanne GalléeCenter for Psychometric Analyses of Aging and Neurodegeneration, Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-9338-2727
Laura E GibbonsCenter for Psychometric Analyses of Aging and Neurodegeneration, Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0001-5054-2543
Seo-Eun ChoiCenter for Psychometric Analyses of Aging and Neurodegeneration, Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-2163-688X
Michael LeeCenter for Psychometric Analyses of Aging and Neurodegeneration, Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-3112-1214
Phoebe ScollardCenter for Psychometric Analyses of Aging and Neurodegeneration, Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-4094-938X
Emily H TrittschuhDepartment of Psychiatry and Behavior Sciences, University of Washington School of Medicine, Seattle, Washington, USA.ORCID 0000-0003-0557-1542
Jesse MezDepartment of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0003-1438-5442
Andrew J SaykinDepartment of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0002-1376-8532
Nancy S FoldiDepartment of Radiology, Brain Health Imaging Institute, Weill Cornell Medicine, New York, New York, USA.ORCID 0000-0001-8810-8558
Shubhabrata MukherjeeCenter for Psychometric Analyses of Aging and Neurodegeneration, Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-2522-2884
Paul K CraneCenter for Psychometric Analyses of Aging and Neurodegeneration, Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-4278-7465
Funding
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI GRABOWSKI, THOMAS J. · 1985 to 2019
$57.2M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
MVP Data Integration into the ADSP Phenotype Harmonization ConsortiumU24AG074855 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CUCCARO, MICHAEL L, HOHMAN, TIMOTHY J · 2021 to 2025
$37.5M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI BRADFORD C DICKERSON · 2019 to 2026
$36.5M
UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DOUGLAS R GALASKO · 2019 to 2026
$34.9M
Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sanjay Asthana · 2019 to 2026
$34.5M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5M
Research Education ComponentP30AG066514 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Margaret Sewell · 2020 to 2026
$31.0M
Yale Alzheimer Disease Research CenterP30AG066508 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER · 2020 to 2026
$30.2M
Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PHILIP L DE JAGER · 2020 to 2026
$30.1M
Research Education ComponentP30AG066468 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI C. Elizabeth Shaaban · 2020 to 2026
introductionEarly-onset Alzheimer's disease dementia (EOAD) is characterized by more pronounced cognitive decline than late-onset AD dementia (LOAD). Characteristic performance in spoken language remains undefined.
methodA cross-sectional analysis of 1189 people with EOAD and 4646 with LOAD from the National Alzheimer's Coordinating Center (NACC) was conducted.
resultBased on data from their first NACC visit with AD, there was considerable heterogeneity in language performance across people with EOAD and LOAD. The distribution of naming ability was similar across these groups. On average, people with LOAD performed better than those with EOAD in category fluency, letter fluency, and spoken lexical retrieval, and had lower Clinical Dementia Rating (CDR) Language scores, although there was considerable overlap in the distributions for participants with EOAD and those with LOAD. DISCUSSION: At diagnosis, the language profiles of EOAD and LOAD are distinct. There is substantial variability in both groups in multiple aspects of language. HIGHLIGHTS: Early-onset Alzheimer's disease (EOAD) is associated with significantly poorer category and phonemic fluency and global spoken lexical retrieval compared to late-onset Alzheimer's disease (LOAD) at time of diagnosis. Participants with EOAD dementia show greater severity and variability in clinician-rated language functioning, as measured by Clinical Dementia Rating (CDR) Language scores. No significant group differences were observed in confrontation naming performance between EOAD and LOAD dementia. Findings support that there are distinct profiles of language performance in EOAD and LOAD at time of dementia diagnosis.
Indexed as
Alzheimer DiseaseLanguageAgedAged, 80 and overAge of OnsetCross-Sectional StudiesFemaleHumansLanguage TestsMaleMiddle AgedNeuropsychological TestsAlzheimer's disease dementiaearly‐onsetlanguagelate‐onsetnon‐amnestic
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Facets of language performance in early-onset and late-onset Alzheimer's disease dementia. · full record | OpenQuestion